The Cold Spring Harbor Laboratory (CSHL) Cancer Center (www.cshl.edu/cancercenter) is a vibrant and dynamic cancer research center that strives for excellence. Researchers are committed to using a focused, multidisciplinary and collaborative approach to investigate the molecular cellular basis of human cancer with the goal of improving diagnosis and treatment of ail major forms ofthe disease. The CSHL Cancer Center is organized into three Scientific Programs. The Gene Expression &Cell Proliferation Program focuses on the regulation of gene expression, cell division cycle control and chromosome structure, comparing normal and cancer cells with a goal to identify new therapeutic targets. The Signal Transduction Program focuses on signal transduction pathways and cell architecture in normal and cancer cells, with a growing emphasis on tumor micro-environment and understanding mechanisms of resistance to targeted therapies. The Cancer Genetics Program focuses on understanding the genetic basis of cancer, tumor progression and discovery of new targets for therapy using innovative mouse models for human cancer. In addition, the CSHL Cancer Center supports ten scientific shared resources. These shared resources provide access to technologies, products, services and expertise that promote multidisciplinary interactions and collaborations among CSHL researchers and programs. Importantly, the shared resources increase productivity, provide economies of scale, decrease wasteful duplication of resources, maintain quality control, and facilitate access to expensive equipment and highly skilled technical services. In the last five years, the CSHL Cancer Center not only broke new ground in understanding cancer genetics and tumor biology, but also achieved its vision of a cancer discovery pipeline that integrates complex cellular processes and pathways in tumor cells with cell biology and biochemistry, human cancer genetics, RNAi technology and innovative animal models that mimic different subsets of human cancers. The pipeline has generated a wealth of pre-clinical data including information on new cancer genes and diagnostic tools, has identified potential new therapeutic targets, has investigated new biochemical pathways, and studied drug resistance mechanisms.

Public Health Relevance

Despite the discovery of targeted therapies that cure or control some cancer types, cancer remains one of the major causes of death in the US. The focus of the Cold Spring Harbor Laboratory Cancer Center is to understand the underlying genetic and cellular basis for the disease and to discover new, targeted and safe cancer therapies that are linked to the patient's tumor genetics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA045508-26
Application #
8473659
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-08-01
Project End
2016-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
26
Fiscal Year
2013
Total Cost
$4,077,038
Indirect Cost
$1,919,875
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Krishnan, Navasona; Bonham, Christopher A; Rus, Ioana A et al. (2018) Harnessing insulin- and leptin-induced oxidation of PTP1B for therapeutic development. Nat Commun 9:283
Pommier, Arnaud; Anaparthy, Naishitha; Memos, Nicoletta et al. (2018) Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science 360:
Krishnan, Navasona; Felice, Christy; Rivera, Keith et al. (2018) DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson's disease. Genes Dev 32:944-952
Tiriac, Herve; Bucobo, Juan Carlos; Tzimas, Demetrios et al. (2018) Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointest Endosc 87:1474-1480
Nattestad, Maria; Goodwin, Sara; Ng, Karen et al. (2018) Complex rearrangements and oncogene amplifications revealed by long-read DNA and RNA sequencing of a breast cancer cell line. Genome Res 28:1126-1135
Connell, Claire M; Raby, Sophie E M; Beh, Ian et al. (2018) Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist 23:116-117
Wong, Mandy S; Kinney, Justin B; Krainer, Adrian R (2018) Quantitative Activity Profile and Context Dependence of All Human 5' Splice Sites. Mol Cell 71:1012-1026.e3
Snider, Justin M; Snider, Ashley J; Obeid, Lina M et al. (2018) Probing de novo sphingolipid metabolism in mammalian cells utilizing mass spectrometry. J Lipid Res 59:1046-1057
Stacchiotti, Silvia; Mir, Olivier; Le Cesne, Axel et al. (2018) Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist 23:62-70
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 33:527-541.e8

Showing the most recent 10 out of 380 publications